VolitionRX (NYSEAMERICAN:VNRX) Shares to Reverse Split on Tuesday, April 28th

VolitionRX Limited (NYSEAMERICAN:VNRX)’s stock is set to reverse split on the morning of Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX Trading Down 8.7%

NYSEAMERICAN:VNRX traded down $0.02 during mid-day trading on Monday, hitting $0.16. The company had a trading volume of 2,461,723 shares, compared to its average volume of 9,794,742. The business has a fifty day simple moving average of $0.20 and a 200-day simple moving average of $0.29. VolitionRX has a 1 year low of $0.15 and a 1 year high of $0.94. The firm has a market capitalization of $25.86 million, a price-to-earnings ratio of -0.74 and a beta of 1.33.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings data on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.71 million. As a group, research analysts anticipate that VolitionRX will post -0.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday. Citigroup cut shares of VolitionRX to a “hold” rating in a research report on Monday. Finally, HC Wainwright decreased their target price on shares of VolitionRX from $1.50 to $1.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $2.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VNRX. Armistice Capital LLC lifted its holdings in VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares during the last quarter. Lagoda Investment Management L.P. increased its holdings in shares of VolitionRX by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares during the last quarter. Citadel Advisors LLC raised its position in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. Squarepoint Ops LLC bought a new position in VolitionRX during the fourth quarter worth $34,000. Finally, Jane Street Group LLC acquired a new position in VolitionRX in the fourth quarter worth $28,000. 8.09% of the stock is currently owned by institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.